The treatment goals of people recently diagnosed with schizophrenia using best–worst scaling

John F.P. Bridges, Kathleen Beusterien, Stephan Heres, Pedro Such, Joaquín Sánchez-Covisa, Anna Greta Nylander, Elcie Chan, Anne de Jong-Laird

Research output: Contribution to journalArticle

Abstract

Objective: This study seeks to quantify the treatment goals of people recently diagnosed with schizophrenia and explore their impact on treatment plan. Methods: People aged 18–35 years with a confirmed diagnosis of schizophrenia within the past 5 years were surveyed in the UK, Germany, and Italy. Treatment goals were assessed via a validated best–worst scaling instrument, where participants evaluated subsets of 13 possible treatment goals identified using a balanced incomplete block design. Participants identified the most and least important goals within each task. Data were also collected on current treatment and preference for daily oral versus long-acting injectable (LAI) treatment. Hierarchical Bayes was used to identify preference weights for the goals, and latent class analysis was used to identify segments of people with similar goals. The segments were compared with the current treatment and preference for oral versus LAI treatment. Results: Across 100 participants, the average age was 26 years, 75% were male and 50% were diagnosed within 2 years ago. Overall, preferences were most favorable for reduced disease symptoms, think clearly, reduced hospitalizations, reduced anxiety, and take care of self. A total of 61% preferred oral medication and 39% LAI. Two groups were identified with different treatment goals; 50% of participants emphasized clinical goals, including reduced disease symptoms (preference weight =19.7%), reduced hospitalizations (15.5%), and reduced anxiety (10.5%). The other 50% emphasized functional goals, including improved relationships with family/friends (11.4%), increased interest in work (10.6%), experiencing a fuller range of emotions (8.4%), and ability to socialize (7.5%). Those emphasizing functional goals were more likely to be on LAI (44% versus 26%; p=0.059) and preferred LAI (46% versus 32%; p=0.151). Conclusions: People with recent-onset schizophrenia may focus more on clinical goals or functional goals, a discussion of which may help facilitate patient engagement.

Original languageEnglish (US)
Pages (from-to)63-70
Number of pages8
JournalPatient Preference and Adherence
Volume12
DOIs
StatePublished - Jan 1 2018

Fingerprint

schizophrenia
scaling
Schizophrenia
hospitalization
anxiety
Disease
Therapeutics
Injections
medication
Italy
emotion
Hospitalization
Anxiety
Patient Participation
ability
Weights and Measures
Aptitude
Self Care
Group
Germany

Keywords

  • Preferences
  • Recent-onset schizophrenia
  • Treatment goals

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Social Sciences (miscellaneous)
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
  • Health Policy

Cite this

Bridges, J. F. P., Beusterien, K., Heres, S., Such, P., Sánchez-Covisa, J., Nylander, A. G., ... de Jong-Laird, A. (2018). The treatment goals of people recently diagnosed with schizophrenia using best–worst scaling. Patient Preference and Adherence, 12, 63-70. https://doi.org/10.2147/PPA.S152870

The treatment goals of people recently diagnosed with schizophrenia using best–worst scaling. / Bridges, John F.P.; Beusterien, Kathleen; Heres, Stephan; Such, Pedro; Sánchez-Covisa, Joaquín; Nylander, Anna Greta; Chan, Elcie; de Jong-Laird, Anne.

In: Patient Preference and Adherence, Vol. 12, 01.01.2018, p. 63-70.

Research output: Contribution to journalArticle

Bridges, JFP, Beusterien, K, Heres, S, Such, P, Sánchez-Covisa, J, Nylander, AG, Chan, E & de Jong-Laird, A 2018, 'The treatment goals of people recently diagnosed with schizophrenia using best–worst scaling', Patient Preference and Adherence, vol. 12, pp. 63-70. https://doi.org/10.2147/PPA.S152870
Bridges, John F.P. ; Beusterien, Kathleen ; Heres, Stephan ; Such, Pedro ; Sánchez-Covisa, Joaquín ; Nylander, Anna Greta ; Chan, Elcie ; de Jong-Laird, Anne. / The treatment goals of people recently diagnosed with schizophrenia using best–worst scaling. In: Patient Preference and Adherence. 2018 ; Vol. 12. pp. 63-70.
@article{bf0648063bf84683be9d859f8f4231fd,
title = "The treatment goals of people recently diagnosed with schizophrenia using best–worst scaling",
abstract = "Objective: This study seeks to quantify the treatment goals of people recently diagnosed with schizophrenia and explore their impact on treatment plan. Methods: People aged 18–35 years with a confirmed diagnosis of schizophrenia within the past 5 years were surveyed in the UK, Germany, and Italy. Treatment goals were assessed via a validated best–worst scaling instrument, where participants evaluated subsets of 13 possible treatment goals identified using a balanced incomplete block design. Participants identified the most and least important goals within each task. Data were also collected on current treatment and preference for daily oral versus long-acting injectable (LAI) treatment. Hierarchical Bayes was used to identify preference weights for the goals, and latent class analysis was used to identify segments of people with similar goals. The segments were compared with the current treatment and preference for oral versus LAI treatment. Results: Across 100 participants, the average age was 26 years, 75{\%} were male and 50{\%} were diagnosed within 2 years ago. Overall, preferences were most favorable for reduced disease symptoms, think clearly, reduced hospitalizations, reduced anxiety, and take care of self. A total of 61{\%} preferred oral medication and 39{\%} LAI. Two groups were identified with different treatment goals; 50{\%} of participants emphasized clinical goals, including reduced disease symptoms (preference weight =19.7{\%}), reduced hospitalizations (15.5{\%}), and reduced anxiety (10.5{\%}). The other 50{\%} emphasized functional goals, including improved relationships with family/friends (11.4{\%}), increased interest in work (10.6{\%}), experiencing a fuller range of emotions (8.4{\%}), and ability to socialize (7.5{\%}). Those emphasizing functional goals were more likely to be on LAI (44{\%} versus 26{\%}; p=0.059) and preferred LAI (46{\%} versus 32{\%}; p=0.151). Conclusions: People with recent-onset schizophrenia may focus more on clinical goals or functional goals, a discussion of which may help facilitate patient engagement.",
keywords = "Preferences, Recent-onset schizophrenia, Treatment goals",
author = "Bridges, {John F.P.} and Kathleen Beusterien and Stephan Heres and Pedro Such and Joaqu{\'i}n S{\'a}nchez-Covisa and Nylander, {Anna Greta} and Elcie Chan and {de Jong-Laird}, Anne",
year = "2018",
month = "1",
day = "1",
doi = "10.2147/PPA.S152870",
language = "English (US)",
volume = "12",
pages = "63--70",
journal = "Patient Preference and Adherence",
issn = "1177-889X",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - The treatment goals of people recently diagnosed with schizophrenia using best–worst scaling

AU - Bridges, John F.P.

AU - Beusterien, Kathleen

AU - Heres, Stephan

AU - Such, Pedro

AU - Sánchez-Covisa, Joaquín

AU - Nylander, Anna Greta

AU - Chan, Elcie

AU - de Jong-Laird, Anne

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Objective: This study seeks to quantify the treatment goals of people recently diagnosed with schizophrenia and explore their impact on treatment plan. Methods: People aged 18–35 years with a confirmed diagnosis of schizophrenia within the past 5 years were surveyed in the UK, Germany, and Italy. Treatment goals were assessed via a validated best–worst scaling instrument, where participants evaluated subsets of 13 possible treatment goals identified using a balanced incomplete block design. Participants identified the most and least important goals within each task. Data were also collected on current treatment and preference for daily oral versus long-acting injectable (LAI) treatment. Hierarchical Bayes was used to identify preference weights for the goals, and latent class analysis was used to identify segments of people with similar goals. The segments were compared with the current treatment and preference for oral versus LAI treatment. Results: Across 100 participants, the average age was 26 years, 75% were male and 50% were diagnosed within 2 years ago. Overall, preferences were most favorable for reduced disease symptoms, think clearly, reduced hospitalizations, reduced anxiety, and take care of self. A total of 61% preferred oral medication and 39% LAI. Two groups were identified with different treatment goals; 50% of participants emphasized clinical goals, including reduced disease symptoms (preference weight =19.7%), reduced hospitalizations (15.5%), and reduced anxiety (10.5%). The other 50% emphasized functional goals, including improved relationships with family/friends (11.4%), increased interest in work (10.6%), experiencing a fuller range of emotions (8.4%), and ability to socialize (7.5%). Those emphasizing functional goals were more likely to be on LAI (44% versus 26%; p=0.059) and preferred LAI (46% versus 32%; p=0.151). Conclusions: People with recent-onset schizophrenia may focus more on clinical goals or functional goals, a discussion of which may help facilitate patient engagement.

AB - Objective: This study seeks to quantify the treatment goals of people recently diagnosed with schizophrenia and explore their impact on treatment plan. Methods: People aged 18–35 years with a confirmed diagnosis of schizophrenia within the past 5 years were surveyed in the UK, Germany, and Italy. Treatment goals were assessed via a validated best–worst scaling instrument, where participants evaluated subsets of 13 possible treatment goals identified using a balanced incomplete block design. Participants identified the most and least important goals within each task. Data were also collected on current treatment and preference for daily oral versus long-acting injectable (LAI) treatment. Hierarchical Bayes was used to identify preference weights for the goals, and latent class analysis was used to identify segments of people with similar goals. The segments were compared with the current treatment and preference for oral versus LAI treatment. Results: Across 100 participants, the average age was 26 years, 75% were male and 50% were diagnosed within 2 years ago. Overall, preferences were most favorable for reduced disease symptoms, think clearly, reduced hospitalizations, reduced anxiety, and take care of self. A total of 61% preferred oral medication and 39% LAI. Two groups were identified with different treatment goals; 50% of participants emphasized clinical goals, including reduced disease symptoms (preference weight =19.7%), reduced hospitalizations (15.5%), and reduced anxiety (10.5%). The other 50% emphasized functional goals, including improved relationships with family/friends (11.4%), increased interest in work (10.6%), experiencing a fuller range of emotions (8.4%), and ability to socialize (7.5%). Those emphasizing functional goals were more likely to be on LAI (44% versus 26%; p=0.059) and preferred LAI (46% versus 32%; p=0.151). Conclusions: People with recent-onset schizophrenia may focus more on clinical goals or functional goals, a discussion of which may help facilitate patient engagement.

KW - Preferences

KW - Recent-onset schizophrenia

KW - Treatment goals

UR - http://www.scopus.com/inward/record.url?scp=85041553309&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041553309&partnerID=8YFLogxK

U2 - 10.2147/PPA.S152870

DO - 10.2147/PPA.S152870

M3 - Article

C2 - 29379273

AN - SCOPUS:85041553309

VL - 12

SP - 63

EP - 70

JO - Patient Preference and Adherence

JF - Patient Preference and Adherence

SN - 1177-889X

ER -